160 related articles for article (PubMed ID: 36863098)
1. Targeted EpCAM-binding for the development of potent and effective anticancer proteins.
Liu Z; Zhang C; Cui B; Wang Y; Lim K; Li K; Thiery JP; Chen J; Ho CL
Biomed Pharmacother; 2023 May; 161():114443. PubMed ID: 36863098
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.
Xu T; Schulga A; Konovalova E; Rinne SS; Zhang H; Vorontsova O; Orlova A; Deyev SM; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769161
[TBL] [Abstract][Full Text] [Related]
3. Epithelial cell adhesion molecule‑targeting designed ankyrin repeat protein‑toxin fusion Ec1‑LoPE exhibits potent cytotoxic action in prostate cancer cells.
Xu T; Liu Y; Schulga A; Konovalova E; Deyev SM; Tolmachev V; Vorobyeva A
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35315504
[TBL] [Abstract][Full Text] [Related]
4. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
[TBL] [Abstract][Full Text] [Related]
5. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
[TBL] [Abstract][Full Text] [Related]
6. Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation.
Simon M; Stefan N; Borsig L; Plückthun A; Zangemeister-Wittke U
Mol Cancer Ther; 2014 Feb; 13(2):375-85. PubMed ID: 24184633
[TBL] [Abstract][Full Text] [Related]
7. DARPin Ec1-LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker.
Babaee N; Talebkhan Garoosi Y; Karimipoor M; Davami F; Bayat E; Safarpour H; Mahboudi F; Barkhordari F
Mol Biol Rep; 2020 Oct; 47(10):7323-7331. PubMed ID: 32979162
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer.
Houvast RD; Badr N; March T; de Muynck LDAN; Sier VQ; Schomann T; Bhairosingh S; Baart VM; Peeters JAHM; van Westen GJP; Plückthun A; Burggraaf J; Kuppen PJK; Vahrmeijer AL; Sier CFM
Eur J Nucl Med Mol Imaging; 2023 Aug; ():. PubMed ID: 37642704
[TBL] [Abstract][Full Text] [Related]
9. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
[TBL] [Abstract][Full Text] [Related]
10. Effect of Surface Modification of Multifunctional Nanocomposite Drug Delivery Carriers with DARPin on Their Biodistribution
Novoselova M; Chernyshev VS; Schulga A; Konovalova EV; Chuprov-Netochin RN; Abakumova TO; German S; Shipunova VO; Mokrousov MD; Prikhozhdenko E; Bratashov DN; Nozdriukhin DV; Bogorodskiy A; Grishin O; Kosolobov SS; Khlebtsov BN; Inozemtseva O; Zatsepin TS; Deyev SM; Gorin DA
ACS Appl Bio Mater; 2022 Jun; 5(6):2976-2989. PubMed ID: 35616387
[TBL] [Abstract][Full Text] [Related]
11. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension.
Simon M; Frey R; Zangemeister-Wittke U; Plückthun A
Bioconjug Chem; 2013 Nov; 24(11):1955-66. PubMed ID: 24168270
[TBL] [Abstract][Full Text] [Related]
12. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins.
Winkler J; Martin-Killias P; Plückthun A; Zangemeister-Wittke U
Mol Cancer Ther; 2009 Sep; 8(9):2674-83. PubMed ID: 19723880
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system.
Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
Mol Cancer Ther; 2007 Nov; 6(11):3019-27. PubMed ID: 18025286
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.
Vorobyeva A; Konovalova E; Xu T; Schulga A; Altai M; Garousi J; Rinne SS; Orlova A; Tolmachev V; Deyev S
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392820
[TBL] [Abstract][Full Text] [Related]
15. Assessing the use of tumor-specific DARPin-toxin fusion proteins for ex vivo purging of cancer metastases from human ovarian cortex before autotransplantation.
Eijkenboom L; Palacio-Castañeda V; Groenman F; Braat D; Beerendonk C; Brock R; Verdurmen W; Peek R
F S Sci; 2021 Nov; 2(4):330-344. PubMed ID: 35559858
[TBL] [Abstract][Full Text] [Related]
16. EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer.
van den Brand D; van Lith SAM; de Jong JM; Gorris MAJ; Palacio-Castañeda V; Couwenbergh ST; Goldman MRG; Ebisch I; Massuger LF; Leenders WPJ; Brock R; Verdurmen WPR
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630661
[TBL] [Abstract][Full Text] [Related]
17. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells.
Li L; Xiang D; Shigdar S; Yang W; Li Q; Lin J; Liu K; Duan W
Int J Nanomedicine; 2014; 9():1083-96. PubMed ID: 24591829
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation.
Boogerd LSF; Boonstra MC; Prevoo HAJM; Handgraaf HJM; Kuppen PJK; van de Velde CJH; Fish A; Cordfunke RA; Valentijn ARPM; Terwisscha van Scheltinga AG; MacDonald GC; Cizeau J; Premsukh A; Vinkenburg van Slooten ML; Burggraaf J; Sier CFM; Vahrmeijer AL
Surg Oncol; 2019 Mar; 28():1-8. PubMed ID: 30851880
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic Construction of DARPin-Based Targeted Delivery Systems Using Protein Farnesyltransferase and a Capture and Release Strategy.
Zhang Y; Wang Y; Uslu S; Venkatachalapathy S; Rashidian M; Schaefer JV; Plückthun A; Distefano MD
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232839
[TBL] [Abstract][Full Text] [Related]
20. Anti-EpCAM scFv gadolinium chelate: a novel targeted MRI contrast agent for imaging of colorectal cancer.
Khantasup K; Saiviroonporn P; Jarussophon S; Chantima W; Dharakul T
MAGMA; 2018 Oct; 31(5):633-644. PubMed ID: 29737435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
